Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TebeMRD: Tebentafusp in Melanoma With Molecular Relapsed Disease
NCT05315258Phase 2Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Jul 2022
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, TCR-Engineered T Cells, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of tebentafusp in cutaneous melanoma (CM), Uveal melanoma (UM), sponsored by University of Oxford. Started Jul 2022; status: active, not recruiting.
02
Drugs
tebentafusp
03
Conditions
cutaneous melanoma (CM)Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT05315258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05315258.